Dario N. R. Carrara

Amzell Ltd. is a Dutch virtual development pharmaceutical company that specializes in taking candidate or repurposed drugs and devices through to proof of concept or registration for sale to commercial healthcare companies. The private company is based in Hoofddorp, Netherlands, and has subsidiaries in Switzerland. The company focuses on developing well-characterized active substances using innovative platform drug delivery technologies to provide more effective drug delivery, increased efficacy, and improved safety and compliance. One of their products, AMZ001, is a non-invasive topical gel formulation containing 3.06%% diclofenac sodium, which is a nonsteroidal anti-inflammatory drug (NSAID) used for the treatment of pain related to knee osteoarthritis. The CEO of the company is Dario N. R. Carrara.

Amzell Ltd. is a Dutch virtual development pharmaceutical company that specializes in taking candidate or repurposed drugs and devices through to proof of concept or registration for sale to commercial healthcare companies. The private company is based in Hoofddorp, Netherlands, and has subsidiaries in Switzerland. The company focuses on developing well-characterized active substances using innovative platform drug delivery technologies to provide more effective drug delivery, increased efficacy, and improved safety and compliance. One of their products, AMZ001, is a non-invasive topical gel formulation containing 3.06%% diclofenac sodium, which is a nonsteroidal anti-inflammatory drug (NSAID) used for the treatment of pain related to knee osteoarthritis. The CEO of the company is Dario N. R. Carrara.